食道扁平上皮がんの世界市場の予測（～2030年）

世界の食道扁平上皮がんの市場規模は、調査期間にCAGRで8.16%の成長が予測されています。アカラシアの流行や、研究開発と製品の承認の拡大、社会的認知の高まりが市場の発展を促進しています。

地域の考察

北米市場が2022年に最大の市場シェアを占めました。これは、食道疾患の流行が市場への関心を高めているためです。さらに、主要参入企業による、よりよい治療オプションへの投資の高まりも、市場の発展を促進すると予測されます。

欧州市場は、喫煙、タバコ、飲酒傾向の高まりが食道扁平上皮がんの先進の治療オプションへの関心を高めていることから、第2位の市場シェアを占めています。さらに、医療サービスの利用の増加も市場の発展を後押しすると予測されます。

アジア太平洋市場は、2023年～2030年に急速な発展が見込まれます。これは食道扁平上皮がんの頻度の上昇や、喫煙人口と飲酒人口の多さなどの要素によるものです。

当レポートでは、世界の食道扁平上皮がん市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

• 概要
• 促進要因
  • アカラシアの流行
  • 研究活動と製品の承認の増加
  • 人々の意識の向上
• 抑制要因
  • 高い治療費
  • 食道がん治療薬の副作用
• 機会
  • 臨床試験の増加

第5章 市場要因の分析

• バリューチェーン分析
  • 研究開発・設計
  • 製造
  • 流通・販売
  • 販売後モニタリング
• ポーターのファイブフォース分析モデル
• 世界の食道扁平上皮市場に対するCOVID-19の影響
  • 需要に対する影響
  • サプライチェーンに対する影響
  • 市場参入企業に対する影響
• 食道扁平上皮がん患者の総数：地域別
• 食道扁平上皮がん患者の予測（2018年～2024年）
• 治療に向けた標準治療（SOC）
  • 手術の標準治療（SOC）
  • 化学療法の標準治療（SOC）
  • 放射線治療の標準治療（SOC）
  • 免疫療法の標準治療（SOC）
  • その他の療法の標準治療（SOC）

第6章 世界の食道扁平上皮がん市場：診断・治療別

• 概要
• 診断
  • 内視鏡検査
  • CTスキャン
  • 食道造影
  • 陽電子放出断層撮影（PET）
  • その他
• 治療
  • 手術
  • 化学療法
  • 放射線治療
  • 免疫療法
  • その他

第7章 世界の食道扁平上皮がん市場：エンドユーザー別

• 概要
  • 病院
  • 専門センター
  • その他

第8章 世界の食道扁平上皮がん市場：地域別

• 世界
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• その他の地域
  • 中東
  • アフリカ
  • ラテンアメリカ

第9章 競合情勢

• 概要
• 競合ベンチマーキング
• 世界の食道扁平上皮がん市場における主な成長戦略
• 世界の食道扁平上皮がん市場における開発数の主要企業
• 主な発展と成長戦略
  • 製品の発売/製品の承認
• 財務マトリクス
  • 売上（2021年）
  • 研究開発支出（2021年）

第10章 企業プロファイル

• F. HOFFMANN-LA ROCHE LTD
• ASTRAZENECA
• CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
• SEAGEN INC.
• ELI LILLY AND COMPANY
• GLAXOSMITHKLINE PLC
• NOVARTIS AG
• BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
• JACOBIO PHARMACEUTICALS GROUP CO., LTD.

第11章 付録

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
• TABLE 3 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 4 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CT SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ESOPHAGRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 19 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 26 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 31 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 35 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 39 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 44 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 48 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 52 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 56 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 60 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 64 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
• TABLE 68 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115 MAJOR PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• TABLE 116 MOST ACTIVE PLAYER IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• TABLE 117 PRODUCT LAUNCHES/PRODUCT APPROVALS
• TABLE 118 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
• TABLE 119 ASTRAZENECA: PRODUCTS OFFERED
• TABLE 120 ASTRAZENECA: KEY DEVELOPMENTS
• TABLE 121 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
• TABLE 122 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: KEY DEVELOPMENTS
• TABLE 123 SEAGEN INC: PRODUCTS OFFERED
• TABLE 124 SEAGEN INC.: KEY DEVELOPMENTS
• TABLE 125 ELI LILLY AND COMPANY: PRODUCTS OFFERED
• TABLE 126 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
• TABLE 127 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
• TABLE 128 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 129 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.: PRODUCTS OFFERED
• TABLE 130 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• FIGURE 5 DRIVER IMPACT ANALYSIS
• FIGURE 6 RESTRAINT IMPACT ANALYSIS
• FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• FIGURE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; GENDER SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2021 & 2030 (USD MILLION)
• FIGURE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS, 2021 & 2030 (USD MILLION)
• FIGURE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)
• FIGURE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2021 & 2030 (USD MILLION)
• FIGURE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (% SHARE)
• FIGURE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (USD MILLION)
• FIGURE 17 NORTH AMERICA MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
• FIGURE 18 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
• FIGURE 19 EUROPE MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
• FIGURE 20 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
• FIGURE 21 ASIA-PACIFIC: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
• FIGURE 22 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
• FIGURE 23 REST OF THE WORLD: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
• FIGURE 24 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE (%), BY COUNTRY, 2021
• FIGURE 25 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 26 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• FIGURE 27 SALES, 2021
• FIGURE 28 RESEARCH & DEVELOPMENT EXPENDITURE, 2021
• FIGURE 29 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 30 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
• FIGURE 31 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 ASTRAZENECA: SWOT ANALYSIS
• FIGURE 33 SEAGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 ELI LILLY AND COMPANY: SWOT ANALYSIS
• FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
• FIGURE 38 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 39 NOVARTIS AG: SWOT ANALYSIS
• FIGURE 40 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: FINANCIAL OVERVIEW

Market Overview

The Esophageal Squamous Cell Carcinoma Market is anticipated to register a CAGR) of 8.16% during the review period. The developing expanding commonness of Achalasia expanded research exercises and item endorsements, and rising public mindfulness are driving market development.

The rising commonness of achalasia help market development because achalasia patients have a higher gamble of Esophageal Squamous Cell Carcinoma than everybody. The diary Archives of Throat reports that 9 to 10 individuals for every 100,000 individuals experience achalasia every year.

Besides, as per the Global Organization for Research on Malignant growth, these rates are 15 and multiple times higher, separately, than the gamble of Esophageal Squamous Cell Carcinoma in everyone. Accordingly, expanding pervasiveness of achalasia will straightforwardly influence the market development of worldwide Esophageal Squamous Cell Carcinoma decidedly.

Market Segmentation

The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into Endoscopy, CT scan, Esophagram, Positron Emission Tomography (PET) and others.

The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.

Regional Insights

The North America Esophageal Squamous Cell Carcinoma market represented the biggest market share in 2022. This is because of the rising pervasiveness of esophageal disease which is raising the interest for the Esophageal Squamous Cell Carcinoma treatment market. Additionally, the rising speculation by significant vital participants in better treatment options is likewise expected to cultivate North America's market development.

Europe Esophageal Squamous Cell Carcinoma market represents the second-biggest market share because of the rising tendency towards smoke, tobacco, and drink is driving up interest for a high-level treatment choice for Esophageal Squamous Cell Carcinoma. Additionally, rising medical services use is likewise expected to help the development of the market.

The Asia-Pacific Esophageal Squamous Cell Carcinoma market is supposed to develop at a critical offer from 2023 to 2030. This is because of elements, for example, the rising frequency of Esophageal Squamous Cell Carcinoma, and the high populace of tobacco smoking and liquor savoring this area is additionally expected to support the market development. Besides, the Rising actual inertia and unfortunate way of life are additionally expected to support the development of the provincial market. Additionally, China market of Esophageal Squamous Cell Carcinoma is supposed to hold the biggest market offer, and Rest of Asia-Pacific market is normal quickest developing district.

The Rest of the World is sectioned into the Middle East, Africa, and Latin America. The market in the previously mentioned districts is probably going to observe development because of solid epidemiological factors, and further developing medical services offices, expanding mindfulness about sound ways of life.

Major Players

Key Companies in the market of Esophageal Squamous Cell Carcinoma include Hoffmann-La Roche Ltd, AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Seagen Inc., Eli Lilly and Company, Glaxosmithkline Plc, Novartis AG, Beijing Shenzhou, Cell Biotechnology Group Co., Ltd., and Jacobio Pharmaceuticals Group Co., Ltd.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF ACHALASIA
  • 4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS
  • 4.2.3 RISING PUBLIC AWARENESS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT
  • 4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS
• 4.4 OPPORTUNITIES
  • 4.4.1 RISE IN CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON MARKET PLAYERS)
• 5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION
• 5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)
• 5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT
  • 5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:
  • 5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:
  • 5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:
  • 5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:
  • 5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS

6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT

• 6.1 OVERVIEW
• 6.2 DIAGNOSIS
  • 6.2.1 ENDOSCOPY
  • 6.2.2 CT SCAN
  • 6.2.3 ESOPHAGRAM
  • 6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)
  • 6.2.5 OTHERS
• 6.3 TREATMENT
  • 6.3.1 SURGERY
  • 6.3.2 CHEMOTHERAPY
  • 6.3.3 RADIOTHERAPY
  • 6.3.4 IMMUNOTHERAPY
  • 6.3.5 OTHERS

7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER

• 7.1 OVERVIEW
  • 7.1.1 HOSPITALS
  • 7.1.2 SPECIALTY CENTERS
  • 7.1.3 OTHERS

8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION

• 8.1 GLOBAL
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 UK
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 AUSTRALIA
  • 8.4.5 SOUTH KOREA
  • 8.4.6 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 AFRICA
  • 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
• 9.6 FINANCIAL MATRIX
  • 9.6.1 SALES (USD MILLION), 2021
  • 9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

• 10.1 F. HOFFMANN-LA ROCHE LTD
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 ASTRAZENECA
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
  • 10.3.1 COMPANY OVERVIEWS
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 SEAGEN INC.
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 ELI LILLY AND COMPANY
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 GLAXOSMITHKLINE PLC
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 NOVARTIS AG
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS